- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01055522
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma
This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
The study is divided in two parts: a phase IIa part, designed to establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine, as well as to determine the preliminary tolerability profile; the second phase IIb part evaluates the objective response rate (ORR) including a randomized study with a fixed dose of Dacarbazine with or without L19IL2, dosed at the RD determined in phase IIa.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dose limiting toxicity will be assessed during the dose-escalation part of Phase IIa from day 1 through day 21 of the first cycle.
Response will be measured using RECIST criteria every 6 weeks (after every 2 cycles of treatment). Patients with stable or responding disease at each assessment may receive additional treatment for a maximum of 6 cycles of induction. Patients with stable or responding disease after induction may receive L19IL2 (without dacarbazine) every 2 weeks as maintenance therapy.
Tumor expression of ED-B FN and tumor uptake of L19IL2 and of Dacarbazine will be assessed via immunohistochemistry and/or other methods deemed appropriate on tumor tissue biopsies. Tumor biopsy will be performed on superficial accessible cutaneous and/or subcutaneous lesions only. Tumor biopsy will be considered optional and will not preclude patient entry on to study should the patient refuse.
Pharmacokinetics of L19IL2, Dacarbazine and AIC will be assessed from serial blood samples using standard methods.
Overall response rate, PFS, survival rate at 6 and 12 months, and overall survival time for all patients and separately for the patients in the Phase IIb part will be assessed using standard methods.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- Universitätsklinik Graz
-
-
-
-
-
Berlin, Germany
- Charité- Universitätsmedizin Berlin
-
Kiel, Germany
- Universitätsklinikum Schleswig-Holstein-Campus Kiel
-
Tuebingen, Germany, 72076
- University Hospital
-
-
-
-
-
Ancona, Italy
- A.O. UNIVERSITARIA OSPEDALI RIUNITI - OSPEDALE UMBERTO I DI ANCONA - ANCONA (AN) (Italy)
-
Milan, Italy, 20141
- European Institute of Oncology
-
Napoli, Italy
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli
-
Siena, Italy
- Azienda Ospedaliera Universitaria Senese
-
-
Tuscany
-
Pisa, Tuscany, Italy, 56126
- University Hospital Pisa
-
-
-
-
-
Zürich, Switzerland
- Universitäts Spital Zürich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed unresectable metastatic (stage IV) non-uveal melanoma
- Age > 18 years
- Measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria. Cutaneous lesions measuring at least 1 cm will be considered measurable.
Prior therapy for metastatic melanoma:
- Phase IIa - Dose definition: prior therapy allowed, including prior chemotherapy; previous treatment with DTIC: patients should be treated > 6 months prior to study entry
- Phase IIb -Activity Evaluation: no prior therapy except radiation. However, if radiation has been administered to a lesion, there must be radiographic evidence of progression of that lesion in order for that lesion to constitute measurable disease or to be included in the measured target lesions
- Fewer than 3 organs involved or cutaneous and/or subcutaneous metastasis only, for PhaseIIb patients
- ECOG performance status < 2
- Life expectancy of at least 12 weeks
- Absolute neutrophil count > 1.5 x 109/L, hemoglobin > 9.0 g/dL and platelets > 100 x 109/L
- Total bilirubin ≤ 30 µmol/L (or ≤ 2.0 mg/Dl)
- ALT and AST ≤ 2.5 x the upper limit of normal (5.0 x ULN for patients with hepatic involvement with tumor
- LDH < 2.0 x ULN for Phase IIa patients and normal LDH for the Phase IIb ones.
- Serum creatinine < 1.5 x ULN
- All toxic effects of prior therapy must have resolved to ≤ Grade 1 unless otherwise specified above
- Negative serum pregnancy test (for women of child-bearing potential only) at screening
Exclusion criteria:
- Primary ocular melanoma
- Evidence of brain metastases, negative CT scan within two months before study commence
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated < 5 years prior to study entry
- History of HIV infection or chronic hepatitis B or C
- Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
- Inadequately controlled cardiac arrhythmias including atrial fibrillation
- History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
- Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).
- Uncontrolled hypertension.
- Ischemic peripheral vascular disease (Grade Iib-IV).
- Severe diabetic retinopathy.
- Active autoimmune disease
- History of organ allograft or stem cell transplantation.
- Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment.
- Known history of allergy to IL2, dacarbazine, or other intravenously administered human proteins/peptides/antibodies.
- Breast feeding female.
- Anti-tumor therapy within 4 weeks of the administration of study treatment.
- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.
- Previous DTIC treatment in the last 6 months prior to study entry
- Growth factors or immunomodulatory agents within 7 days of the administration of study treatment.
- Patient requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
- Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARM 1: L19IL2 + Dacarbazin
|
RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles. Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles. Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment. DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first |
EXPERIMENTAL: ARM 2: L19IL2 + Dacarbazin
|
RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment. DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first |
ACTIVE_COMPARATOR: ARM 3: Dacarbazin
DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
|
Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of Dacarbazine
Time Frame: 21 days
|
21 days
|
To evaluate Objective response rate (ORR) by CT or MRI
Time Frame: 18 weeks
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the Pharmacokinetics of L19IL2, dacarbazine and 5-aminoimidazole -4 carboxamide (AIC).
Time Frame: 42 days
|
42 days
|
To investigate the induction of human anti-fusion protein antibodies (HAFA)
Time Frame: 1 year
|
1 year
|
To investigate Antitumor activity of L19IL2 with dacarbazine in patients with metastatic melanoma by TC or MRI
Time Frame: 18 weeks
|
18 weeks
|
Evaluation of the immunological activity of study treatment
Time Frame: 1 year
|
1 year
|
To estimate progression -free survival (PFS)
Time Frame: 1 year
|
1 year
|
To estimate overall survival (OS)
Time Frame: 1 year
|
1 year
|
To assess safety and tolerability
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Chiara Matilde Catania, Dr, European Istitute of Oncology Milan (Italy)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Dacarbazine
- Interleukin-2
Other Study ID Numbers
- PH-L19IL2DTIC-03/07
- 2007-005737-11 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Melanoma
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditionsUnited States
-
GlaxoSmithKlineWithdrawnCancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
-
Elizabeth DavisBristol-Myers SquibbTerminatedMetastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II ExpressionUnited States
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
Provectus Biopharmaceuticals, Inc.Active, not recruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Uveal Melanoma | Metastatic Pancreatic Cancer | Metastatic Colon Cancer | Metastatic Ocular Melanoma | Cancer Metastatic to the LiverUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
Clinical Trials on Arm 1: L19IL2 + Dacarbazine
-
Jonsson Comprehensive Cancer CenterAmerican Cancer Society, Inc.Completed
-
VA Office of Research and DevelopmentCompletedSpinal Cord InjuriesUnited States
-
Hôpital NOVOCompletedHemiplegia and/or Hemiparesis Following StrokeFrance
-
Morehouse School of MedicineNational Cancer Institute (NCI)UnknownColorectal CancerUnited States
-
The University of Texas Health Science Center,...Brighter BitesRecruiting
-
Children's Cancer Hospital Egypt 57357CompletedPediatric Brain Stem GliomaEgypt
-
Indiana UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes MellitusUnited States
-
Norwegian University of Science and TechnologyHelse Nord-Trøndelag HFCompletedLow Back PainNorway
-
MD Stem CellsEnrolling by invitationSpinal Cord Diseases | Spinal Cord Injuries | SCI - Spinal Cord Injury | Paraplegia | Spinal Cord Compression | Spinal Cord Ischemia | Paraplegia, Spinal | Paraplegia; Traumatic | Spinal Paralysis | Paraplegia/ParaparesisUnited States
-
sigma-tau i.f.r. S.p.A.CompletedMalignant MelanomaFrance, Germany, Hungary, Italy, Poland, Portugal, Spain, Switzerland